Circulating biomarkers of tolerance

Transplantation Reviews

Volumn 29, Issue 2, 2015, Pages 68-72

  Girmanova, Eva ^a   Hruba, Petra ^a   Viklicky, Ondrej ^a  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

B LYMPHOCYTE; BLOOD; BONE MARROW; CELL POPULATION; CLINICAL EVALUATION; GENE EXPRESSION; GRAFT RECIPIENT; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; LIVER GRAFT; NATURAL KILLER CELL; NONHUMAN; ORGAN TRANSPLANTATION; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; TRANSPLANTATION TOLERANCE; ADVERSE EFFECTS; IMMUNOLOGICAL MONITORING; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; PHYSIOLOGY; T LYMPHOCYTE SUBPOPULATION;

B-LYMPHOCYTE SUBSETS; BIOMARKERS; HUMANS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MONITORING, IMMUNOLOGIC; T-LYMPHOCYTE SUBSETS; TRANSPLANTATION TOLERANCE;

EID: 84928214189     PISSN: 0955470X     EISSN: 15579816     Source Type: Journal    
DOI: 10.1016/j.trre.2015.01.003     Document Type: Review

References (56)

1. Sellares J., de Freitas D.G., Mengel M., et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 2012, 12:388-399.
2. Lopez M.M., Valenzuela J.E., Alvarez F.C., Lopez-Alvarez M.R., Cecilia G.S., Paricio P.P. Long-term problems related to immunosuppression. Transpl Immunol 2006, 17:31-35.
3. Scandling J.D., Busque S., Dejbakhsh-Jones S., et al. Tolerance and withdrawal of immunosuppressive drugs in patients given kidney and hematopoietic cell transplants. Am J Transplant 2012, 12:1133-1145.
4. Leventhal J., Abecassis M., Miller J., et al. Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation. Sci Transl Med 2012, 4:124-128.
5. Martinez-Llordella M., Puig-Pey I., Orlando G., et al. Multiparameter immune profiling of operational tolerance in liver transplantation. Am J Transplant 2007, 7:309-319.
6. Sagoo P., Perucha E., Sawitzki B., et al. Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J Clin Invest 2010, 120:1848-1861.
7. Newell K.A., Asare A., Kirk A.D., et al. Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest 2010, 120:1836-1847.
8. Billingham R.E., Brent L., Medawar P.B. Actively acquired tolerance of foreign cells. Nature 1953, 172:603-606.
9. Remuzzi G., Ferrazzi P., Bontempelli M., et al. Preliminary results of intrathymic injection of donor cells to prevent acute rejection in human heart transplantation. J Am Soc Nephrol 1995, 6:1291-1294.
10. Ashton-Chess J., Brouard S., Soulillou J.P. Is clinical tolerance realistic in the next decade?. Transpl Int 2006, 19:539-548.
11. Jacquet E.G., Schanie C.L., Fugier-Vivier I., Willer S.S., Ildstad S.T. Facilitating cells as a venue to establish mixed chimerism and tolerance. Pediatr Transplant 2003, 7:348-357.
12. Exner B.G., Acholonu I.N., Bergheim M., Mueller Y.M., Ildstad S.T. Mixed allogeneic chimerism to induce tolerance to solid organ and cellular grafts. Acta Haematol 1999, 101:78-81.
13. Ildstad S.T., Sachs D.H. Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts. Nature 1984, 307:168-170.
14. Fudaba Y., Spitzer T.R., Shaffer J., et al. Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: in vivo and in vitro analyses. Am J Transplant 2006, 6:2121-2133.
15. Kawai T., Cosimi A.B., Spitzer T.R., et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2008, 358:353-361.
16. Brouard S., Pallier A., Renaudin K., et al. The natural history of clinical operational tolerance after kidney transplantation through twenty-seven cases. Am J Transplant 2012, 12:3296-3307.
17. Sanchez-Fueyo A. Tolerance profiles and immunosuppression. Liver Transpl 2013, 19:S44-S48.
18. Lerut J., Sanchez-Fueyo A. An appraisal of tolerance in liver transplantation. Am J Transplant 2006, 6:1774-1780.
19. Chong A.S., Alegre M.L. Transplantation tolerance and its outcome during infections and inflammation. Immunol Rev 2014, 258:80-101.
20. Silva H.M., Takenaka M.C., Moraes-Vieira P.M., et al. Preserving the B-cell compartment favors operational tolerance in human renal transplantation. Mol Med 2012, 18:733-743.
21. Pallier A., Hillion S., Danger R., et al. Patients with drug-free long-term graft function display increased numbers of peripheral B cells with a memory and inhibitory phenotype. Kidney Int 2010, 78:503-513.
22. Li Y., Koshiba T., Yoshizawa A., et al. Analyses of peripheral blood mononuclear cells in operational tolerance after pediatric living donor liver transplantation. Am J Transplant 2004, 4:2118-2125.
23. Baeten D., Louis S., Braud C., et al. Phenotypically and functionally distinct CD8+ lymphocyte populations in long-term drug-free tolerance and chronic rejection in human kidney graft recipients. J Am Soc Nephrol 2006, 17:294-304.
24. Mazariegos G.V., Zahorchak A.F., Reyes J., et al. Dendritic cell subset ratio in peripheral blood correlates with successful withdrawal of immunosuppression in liver transplant patients. Am J Transplant 2003, 3:689-696.
25. Halloran P.F., de Freitas D.G., Einecke G., et al. The molecular phenotype of kidney transplants. Am J Transplant 2010, 10:2215-2222.
26. Viklicky O., Krystufkova E., Brabcova I., et al. B-cell-related biomarkers of tolerance are up-regulated in rejection-free kidney transplant recipients. Transplantation 2013, 95:148-154.
27. Famulski K.S., Broderick G., Einecke G., et al. Transcriptome analysis reveals heterogeneity in the injury response of kidney transplants. Am J Transplant 2007, 7:2483-2495.
28. Famulski K.S., Sis B., Billesberger L., Halloran P.F. Interferon-gamma and donor MHC class I control alternative macrophage activation and activin expression in rejecting kidney allografts: a shift in the Th1-Th2 paradigm. Am J Transplant 2008, 8:547-556.
29. Braud C., Baeten D., Giral M., et al. Immunosuppressive drug-free operational immune tolerance in human kidney transplant recipients: part I. Blood gene expression statistical analysis. J Cell Biochem 2008, 103:1681-1692.
30. Sivozhelezov V., Braud C., Giacomelli L., et al. Immunosuppressive drug-free operational immune tolerance in human kidney transplants recipients. Part II. Non-statistical gene microarray analysis. J Cell Biochem 2008, 103:1693-1706.
31. Moreso F., Torres I.B., Martinez-Gallo M., et al. Gene expression signature of tolerance and lymphocyte subsets in stable renal transplants: results of a cross-sectional study. Transpl Immunol 2014, 31:11-16.
32. Hoffmann S.C., Hale D.A., Kleiner D.E., et al. Functionally significant renal allograft rejection is defined by transcriptional criteria. Am J Transplant 2005, 5:573-581.
33. Li B., Hartono C., Ding R., et al. Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine. N Engl J Med 2001, 344:947-954.
34. Sawitzki B., Bushell A., Steger U., et al. Identification of gene markers for the prediction of allograft rejection or permanent acceptance. Am J Transplant 2007, 7:1091-1102.
35. Brouard S., Le Bars A., Dufay A., et al. Identification of a gene expression profile associated with operational tolerance among a selected group of stable kidney transplant patients. Transpl Int 2011, 24:536-547.
36. Keeren K., Friedrich M., Gebuhr I., et al. Expression of tolerance associated gene-1, a mitochondrial protein inhibiting T cell activation, can be used to predict response to immune modulating therapies. J Immunol 2009, 183:4077-4087.
37. Chesneau M., Pallier A., Braza F., et al. Unique B cell differentiation profile in tolerant kidney transplant patients. Am J Transplant 2014, 14:144-155.
38. Desvaux D., Schwarzinger M., Pastural M., et al. Molecular diagnosis of renal-allograft rejection: correlation with histopathologic evaluation and antirejection-therapy resistance. Transplantation 2004, 78:647-653.
39. Seiler M., Brabcova I., Viklicky O., et al. Heightened expression of the cytotoxicity receptor NKG2D correlates with acute and chronic nephropathy after kidney transplantation. Am J Transplant 2007, 7:423-433.
40. Wood K.J., Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003, 3:199-210.
41. Kendal A.R., Chen Y., Regateiro F.S., et al. Sustained suppression by Foxp3+ regulatory T cells is vital for infectious transplantation tolerance. J Exp Med 2011, 208:2043-2053.
42. Sakaguchi S. Regulatory T, cells: key controllers of immunologic self-tolerance. Cell 2000, 101:455-458.
43. Martinez-Llordella M., Lozano J.J., Puig-Pey I., et al. Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. J Clin Invest 2008, 118:2845-2857.
44. Louis S., Braudeau C., Giral M., et al. Contrasting CD25hiCD4+T cells/FOXP3 patterns in chronic rejection and operational drug-free tolerance. Transplantation 2006, 81:398-407.
45. Braudeau C., Racape M., Giral M., et al. Variation in numbers of CD4+CD25highFOXP3+ T cells with normal immuno-regulatory properties in long-term graft outcome. Transpl Int 2007, 20:845-855.
46. Bestard O., Cruzado J.M., Mestre M., et al. Achieving donor-specific hyporesponsiveness is associated with FOXP3+ regulatory T cell recruitment in human renal allograft infiltrates. J Immunol 2007, 179:4901-4909.
47. Baron U., Floess S., Wieczorek G., et al. DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3(+) conventional T cells. Eur J Immunol 2007, 37:2378-2389.
48. Lopez M., Clarkson M.R., Albin M., Sayegh M.H., Najafian N. A novel mechanism of action for anti-thymocyte globulin: induction of CD4+CD25+Foxp3+ regulatory T cells. J Am Soc Nephrol 2006, 17:2844-2853.
49. Sewgobind V.D., Kho M.M., van der Laan L.J., et al. The effect of rabbit anti-thymocyte globulin induction therapy on regulatory T cells in kidney transplant patients. Nephrol Dial Transplant 2009, 24:1635-1644.
50. Krystufkova E., Sekerkova A., Striz I., Brabcova I., Girmanova E., Viklicky O. Regulatory T cells in kidney transplant recipients: the effect of induction immunosuppression therapy. Nephrol Dial Transplant 2012, 27:2576-2582.
51. Kirk A.D., Hale D.A., Mannon R.B., et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation 2003, 76:120-129.
52. Gaber A.O., Knight R.J., Patel S., Gaber L.W. A review of the evidence for use of thymoglobulin induction in renal transplantation. Transplant Proc 2010, 42:1395-1400.
53. Streitz M., Miloud T., Kapinsky M., et al. Standardization of whole blood immune phenotype monitoring for clinical trials: panels and methods from the ONE study. Transplant Res 2013, 2:17.
54. Haynes L.D., Jankowska-Gan E., Sheka A., et al. Donor-specific indirect pathway analysis reveals a B-cell-independent signature which reflects outcomes in kidney transplant recipients. Am J Transplant 2012, 12:640-648.
55. Pallier A., Hillion S., Danger R., Giral M., Racape M., Degauque N., et al. Patients with drug-free long-term graft function display increased numbers of peripheral B cells with a memory and inhibitory phenotype. Kidney Int 2010, 78:503-513.
56. Moraes-Vieira P.M., Silva H.M., Takenaka M.C., et al. Differential monocyte STAT6 activation and CD4(+)CD25(+)Foxp3(+) T cells in kidney operational tolerance transplanted individuals. Hum Immunol 2010, 71:442-450.